It has been shown, that Sp3 binds to the intron 2 region of RAD9A in vivo and that in MCF-7 breast cancer cells and breast cancer tumors with increased RAD9A mRNA this binding site was hypermethylated (Cheng et al., 2005[12]). The gene discussed is SP3; the disease is breast carcinoma.